Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

23.39 +0.52 (+2.25%)
Streaming Delayed Price Updated: 1:17 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Exelixis Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Exelixis Stock Sees Rising Relative Strength Rating
On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before. 
Via Investor's Business Daily
3 Biotech Stocks You’ll Regret Not Buying Soon
These top biotech stocks are must-buys with huge potential, leading the industry with high-rewards for investors. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Via Benzinga
Analyst Expectations for Exelixis's Future
Via Benzinga
Exelixis (EXEL) Q2 2023 Earnings Call Transcript
EXEL earnings call for the period ending June 30, 2023. 
Via The Motley Fool
2 Biotech Growth Stocks I'd Buy Right Now
Both drugmakers seem to have a bright future ahead. 
Via The Motley Fool
8 Analysts Have This to Say About Exelixis
Via Benzinga
Exelixis (EXEL) Q1 2023 Earnings Call Transcript
EXEL earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil
There is opportunity in a crisis. Key biotech stocks amid turmoil could be the greatest deals on the market today. 
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
These are the three bargain biotech stocks showcasing massive upside potential for investors looking to find a position in the sector. 
Via InvestorPlace
3 No-Brainer Stocks to Buy With $200 Right Now
A modest amount of money can go a long way when it's invested in game-changing businesses. 
Via The Motley Fool
The Smartest Stocks to Buy With $20 Right Now and Hold Forever
These companies can take investors on a lucrative ride, and all for the price of a few lattes. 
Via The Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2023
Companies that don't make a lot of noise can still make you a lot of money. 
Via The Motley Fool
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
Both Axsome Therapeutics and Exelixis have potentially game-changing products in their pipelines. 
Via The Motley Fool
Exelixis: Q1 Earnings Insights
Via Benzinga
What 9 Analyst Ratings Have To Say About Exelixis
Via Benzinga
Why Exelixis Stock Leaped More Than 4% Higher Today
Oh, how some investors love stock buyback programs. 
Via The Motley Fool
Analyst Ratings for Exelixis
Via Benzinga
Nasdaq Bear Market: 5 Exceptional Growth Stocks You'll Regret Not Buying on the Dip
A sizable dip in the innovation-driven Nasdaq Composite is the perfect excuse for investors to pounce on some phenomenal deals. 
Via The Motley Fool
Amid Proxy Challenge From Farallon, Exelixis' Board Member Resigns
Exelixis Inc's (NASDAQ: EXEL) board member Lance Willsey announced his resignation from the Board,  
Via Benzinga
The Smartest Stocks to Buy With $20 Right Now and Hold Forever
These cheap stocks have the potential to skyrocket over the long haul. 
Via The Motley Fool
Nasdaq Bear Market: 5 Sensational Growth Stocks You'll Regret Not Buying on the Dip
Opportunistic investors would be wise to pounce on innovative growth stocks following a 33% decline in the Nasdaq Composite. 
Via The Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2023
Both companies have game-changing product portfolios that should result in stock price growth. 
Via The Motley Fool
Facebook Turns To Generative AI For Help, FedEx Consolidates, UBS Executives Say Surprise Credit Suisse Deal 'Major Challenge:' Today's Top Stories
Benzinga 
Via Benzinga
Farallon Capital Might Undertake Proxy Fight Against Exelixis, Nominates Three Directors
Via Benzinga
2 Incredible Stocks to Buy With Less Than $25
Nothing beats a great investment for the price of just a few cups of coffee. 
Via The Motley Fool
Exelixis Stock Shows Rising Relative Price Performance; Still Shy Of Key Benchmark
In a welcome move, Exelixis stock saw its Relative Strength Rating improve to 73 on Monday, up from 69 a day earlier. 
Via Investor's Business Daily
3 Beaten-Down Stocks That Could Soar This Year
These stocks could enjoy big rebounds in 2023. 
Via The Motley Fool
Exelixis Stock Generating Improved Relative Strength Rating
Exelixis stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 69 to 76. 
Via Investor's Business Daily
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.